VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
PHR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
PHRPhreesia, Inc.
$10.95$677M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

PHR logoPhreesia, Inc.(PHR)Earnings, Financials & Key Ratios

PHR•NYSE
$10.95
292.0× P/E·Price updated Jul 7, 2026
SectorHealthcareIndustryHealthcare ITSub-IndustryPatient Engagement, Intake and Payments
AboutPhreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and patient reported outcome (PRO) data for approximately 25 specialties, as well as enables healthcare services clients to communicate with their patients through surveys, announcements, text and email messaging, and health campaigns; and COVID-19 support modules for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Raleigh, North Carolina.Show more
  • Revenue$481M+14.5%
  • EBITDA$25M+182.2%
  • Net Income$2M+103.9%
  • EPS (Diluted)0.04+103.7%
  • Gross Margin67.93%+0.1%
  • EBITDA Margin5.17%+171.8%
  • Operating Margin-1.38%+90.1%
  • Net Margin0.48%+103.4%
  • ROE0.77%+103.4%

PHR Price & Volume

Phreesia, Inc. (PHR) stock price & volume — 10-year historical chart

Loading chart...

Operational Scale Offsets Competitive EHR Platform Risks

Investment Thesis • Updated 2027Q1

VerdictNeutral
Growth:Decelerating
Profitability:Moderate
Financial:Healthy
Cash Flow:Improving
Primary Risk:EHR platform native competition

Key Thesis Takeaways

  • Phreesia is transitioning from a high-growth phase to a mature, self-funding model, evidenced by its first positive quarterly operating income of $7.0 million in 2027Q1.
  • While the company is successfully scaling its revenue streams, investors should monitor the structural threat posed by native EHR intake features and the potential for goodwill impairment given that goodwill has surged to $169.5 million.
  • Future performance will depend on the company's ability to maintain its 13.3% free cash flow margin while managing the significant dilution impact of $13.6 million in quarterly stock-based compensation.

Verdict Logic

while the company achieved a positive operating income of $7.0 million, the high forward P/E of 25.11 and significant stock-based compensation of $13.6 million warrant caution regarding the sustainability of GAAP profitability.

PHR Growth Metrics

Phreesia, Inc. (PHR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years26.45%
3 Years19.6%
TTM14.05%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM121.5%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-8.99%

Return on Capital

10 Years-29.3%
5 Years-31.15%
3 Years-24.33%
Last Year-1.75%

PHR Recent Earnings

Phreesia, Inc. (PHR) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 27, 2026
Metric
Actual
Est
EPS
$0.05+150.0%
$0.02
Rev
$131M+0.7%
$130M
Q2 2026
Mar 30, 2026
Metric
Actual
Est
EPS
$0.12+82.6%
$0.07
Rev
$127M+0.2%
$127M
Q4 2025
Dec 8, 2025
Metric
Actual
Est
EPS
$0.10
$0.00
Rev
$120M+0.3%
$120M
Q4 2025
Sep 4, 2025
Metric
Actual
Est
EPS
$0.01+114.3%
$0.07
Rev
$117M-2.4%
$120M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 27, 2026
$0.05vs $0.02+150.0%
$131Mvs $130M+0.7%
Q2 2026Mar 30, 2026
$0.12vs $0.07+82.6%
$127Mvs $127M+0.2%
Q4 2025Dec 8, 2025
$0.10vs $0.00
$120Mvs $120M+0.3%
Q4 2025Sep 4, 2025
$0.01vs $0.07+114.3%
$117Mvs $120M-2.4%
Based on last 12 quarters of dataView full earnings history →

Latest PHR News

Recent stock market news and headlines for Phreesia, Inc. (PHR)

PRNewsWire·Jun 29, 2026
Phreesia, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PHR

LOS ANGELES, June 29, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Phreesia, Inc. ("Phreesia" or "the Company") (NYSE: PHR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of PHR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

Peers Comparison

Key metrics vs top competitors for Phreesia, Inc. (PHR)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
PHR logoPHRPhreesia, Inc.Current
$10.95$676.84M292.0014.48%0.48%0.77%—
HCAT logoHCATHealth Catalyst, Inc.
$2.27$167.74M-0.891.48%-87.69%-99.78%—
DOCS logoDOCSDoximity, Inc.
$22.74$4.25B23.2013.05%30.4%19.36%—
GDRX logoGDRXGoodRx Holdings, Inc.
$3.03$1.05B35.520.57%3.74%4.75%—
VEEV logoVEEVVeeva Systems Inc.
$192.30$31.24B35.3516.34%28.37%13.36%—
INVA logoINVAInnoviva, Inc.
$22.25$1.64B6.7418.52%118.91%47.59%—

Compare PHR vs Peers

Phreesia, Inc. (PHR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs HCAT

Most directly comparable listed peer for PHR.

Scale Benchmark

vs VEEV

Larger-name benchmark to compare PHR against a more recognizable public peer.

Peer Set

Compare Top 5

vs HCAT, DOCS, GDRX, VEEV

PHR SEC Filings & Documents

Phreesia, Inc. (PHR) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 27, 2026·SEC

Material company update

May 11, 2026·SEC

Material company update

May 4, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 31, 2026·SEC

FY 2025

Mar 13, 2025·SEC

10-Q Quarterly Reports

4
FY 2026

May 28, 2026·SEC

FY 2025

Dec 9, 2025·SEC

FY 2025

Sep 5, 2025·SEC

Get notified when PHR posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

PHR Frequently Asked Questions

Phreesia, Inc. (PHR) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Phreesia, Inc.'s revenue?

Phreesia, Inc. (PHR) reported $495.6M in revenue for fiscal year 2026. This represents a 521% increase from $79.8M in 2018.

How fast is Phreesia, Inc. growing?

Phreesia, Inc. (PHR) grew revenue by 14.5% over the past year. This is steady growth.

Is PHR profitable?

Yes, Phreesia, Inc. (PHR) is profitable, generating $9.2M in net income for fiscal year 2026 (0.5% net margin).

Dividend & Returns
What is PHR's return on equity?

Phreesia, Inc. (PHR) has a return on equity (ROE) of 0.8%. This is below average, suggesting room for improvement.

What is Phreesia, Inc.'s free cash flow?

Phreesia, Inc. (PHR) generated $73.7M in free cash flow for fiscal year 2026. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in PHR back in 2018?

Total return calculator · dividends reinvested · 8+ years of data

See returns →